Human Anti-CD81 Recombinant Antibody (clone CD81K04) (CAT#: FAMAB-1087CQ)

Figure 1 Evaluation of anti-CD81 mAb K04 PK in SCID and uPA11/SCID human liver chimeric mice (PXB mice).

Single 20- or 60-mg/kg doses of K04 Ab were administered SC, and serum concentrations of K04 were determined at different times. (A) PK parameters and (B)concentration-time profiles are shown.

Ji, C., Liu, Y., Pamulapati, C., Bohini, S., Fertig, G., Schraeml, M., ... & Klumpp, K. (2015). Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody. Hepatology, 61(4), 1136-1144.

Figure 2 CD81 mAbs showed broad-spectrum and potent antiviralactivity.

(A and B) PHHs from 5 different donors (except K21, with 3 donors) were infected with HCVpp con1 and treated with serially diluted CD81 mAbs K02, K04, K07, K13, K21, and JS81. Three days later, luciferase activity was measured and IC50 values were determined by using the sigmoidal dose-response model with one binding site in Microsoft XLfit. Individual IC50 values for each mAb and donor are shown in (B), and pooled multidonor hepatocyte HCVpp inhibition curves are shown in(A).

Ji, C., Liu, Y., Pamulapati, C., Bohini, S., Fertig, G., Schraeml, M., ... & Klumpp, K. (2015). Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti‐CD81 monoclonal antibody. Hepatology, 61(4), 1136-1144.